FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

|) | Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) |
|---|---|
| | Instruction 1(b). |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| OMB APPROVAL | | | | | | | | |
|--------------|----------|--|--|--|--|--|--|--|
| OMB Number: | 3235-028 | | | | | | | |

| hours per response: | 0.5 |
|--------------------------|-----|
| Estimated average burden | |
| Ectimated avarage burden | |

| 1. Name and Addres BOGER JOS | ss of Reporting Person HUA_S | n* | 2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX] | | ionship of Reporting Persor all applicable) Director | 10% Owner | | |
|--|---------------------------------|-------|--|---|--|--------------------------|--|--|
| (Last) (First) (Middle) | | | | | Officer (give title below) | Other (specify below) | | |
| C/O VERTEX PHARMACEUTICALS INCORPORATED | | ALS | 3. Date of Earliest Transaction (Month/Day/Year) 05/30/2013 | | | | | |
| 130 WAVERLY ST. | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | |
| (Street) | | | | X | Form filed by One Reporti | ing Person | | |
| CAMBRIDGE | MA | 02139 | | | Form filed by More than C Person | One Reporting | | |
| (City) | (State) | (Zip) | | | | | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transa Code (8) | | | | 5. Amount of Securities Beneficially Owned Following Reported | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |
|---------------------------------|--|---|------------------------------|---|--------|---------------|---|---|---|---|
| | | | Code | v | Amount | (A) or (D) | Price | Transaction(s) (Instr. 3 and 4) | | (1150.4) |
| Common Stock | 05/30/2013 | | М | | 1,400 | A | \$9.07 | 340,295 | D | |
| Common Stock | 05/30/2013 | | S ⁽¹⁾ | | 200 | D | \$80.22 ⁽²⁾⁽³⁾ | 340,095 | D | |
| Common Stock | 05/30/2013 | | S ⁽¹⁾ | | 300 | D | \$81.92(3)(4) | 339,795 | D | |
| Common Stock | 05/30/2013 | | S ⁽¹⁾ | | 900 | D | \$83.16 ⁽³⁾⁽⁵⁾ | 338,895 | D | |
| Common Stock | | | | | | | | 300,000 | I | Common Stock held in trust. ⁽⁶⁾ |
| Common Stock | | | | | | | | 13,286 | I | 401(k) |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | of | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---|---|--|---|------------------------------|---|-----|-------|--|--------------------|--|--|---|--|--|--|
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |
| Employee Stock Option (right to buy) | \$9.07 | 05/30/2013 | | М | | | 1,400 | (7) | 12/10/2013 | Common Stock | 1,400 | \$0.00 | 37,800 | D | |

Explanation of Responses:

1. Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.

2. Open market sales reported on this line occurred at a weighted average price of \$80.22 (range \$79.92 to \$80.51).

3. Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

4. Open market sales reported on this line occurred at a weighted average price of \$81.92 (range \$81.82 to \$82.11).

5. Open market sales reported on this line occurred at a weighted average price of \$83.16 (range \$82.85 to \$83.57).

6. Common stock held in grantor retained annuity trusts.

7. Fully vested.

Remarks:

Kenneth L. Horton, Attorney-<u>In-Fact</u> <u>06/(</u>

06/03/2013

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.